CompletedEUCTR 2004-001500-13

An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesAnxiety

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Ireland · Italy and 3 more locations
Study phase: Phase 3

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 390
Sponsor: Pfizer Ltd.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United Kingdom, Ireland, Italy, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2004-001500-13
Official title: Show the full official title
An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...

Looking for a study you can join?

Explore recruiting studies

Get this study by email

Recruitment & locations

Completed

Ireland · Italy · Spain

2 more locations

Sweden
United Kingdom

Registry details

Historical country statuses

Spain — Completed
United Kingdom — Completed
Ireland — Completed
Italy — Completed
Sweden — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pfizer Ltd.

Want to explore more studies?

Explore studies